Clinical Trials Logo

Clinical Trial Summary

This was a first-in-human, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 as monotherapy or in combination with AK104 in subjects with advanced or metastatic solid tumors.


Clinical Trial Description

The study was conducted across 2 parts. Part A of the study was the dose escalation part of AK117 monotherapy as priming dose to evaluate the safety and tolerability of AK117 weekly dosing in solid tumors. Part B which was to evaluate the optimal maintenance dose of AK117 was not performed as the MAD dose level of AK117 monotherapy was determined in Part A. Part A2 was the dose escalation part of AK117 in combination with AK104 to evaluate the safety and tolerability of AK117 monotherapy in solid tumors. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04349969
Study type Interventional
Source Akeso
Contact
Status Completed
Phase Phase 1
Start date April 23, 2020
Completion date November 8, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04047290 - A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors Phase 1
Active, not recruiting NCT04600206 - Existential Distress in Patients With Advanced Cancer and Their Caregivers
Terminated NCT01243762 - A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) Phase 1
Completed NCT04728334 - A Phase 1 Dose Escalation and Expansion Study of AK117 Phase 1
Terminated NCT01121588 - An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) Phase 1
Recruiting NCT05939687 - Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection Phase 3
Recruiting NCT06018142 - Clinical Application of Super-resolution Ultrasound(SR-US) Imaging in Solid Tumors
Not yet recruiting NCT03903848 - Cancer Survivors Acute Exercise Response 1 N/A
Recruiting NCT05758571 - Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients Phase 1/Phase 2
Completed NCT04637295 - Perceptions, Experiences, and Activity in CancEr Survivors During COVID-19
Completed NCT04479579 - Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery Phase 4
Recruiting NCT04230772 - Clinical Outcomes of NOSES Versus Traditional Robotic-assisted Surgery for Patients With Colorectal Cancer N/A
Not yet recruiting NCT05650385 - A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors Phase 1
Completed NCT04616846 - Thromboembolic Risk Screening in Patients With Cancer and COVID-19 N/A
Recruiting NCT04721756 - Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging Early Phase 1